Location: http://mtest.business-standard.com
Redirect IN else Troubles behind it, Cadila surges ahead | Business Standard

Troubles behind it, Cadila surges ahead

Sohini Das | Ahmedabad Jun 29, 2017 01:11 AM IST

Cadila Healthcare The shares of pharma major Cadila Healthcare, also known as Zydus Cadila, have been on a roll for the past few weeks. The stock's value rose almost 55 per cent to a six-month high of Rs 548.35 on June 12. Cadila has edged past Lupin to become the second-most valuable pharmaceutical company by market capitalisation at Rs 54,719 crore. There were two triggers behind this sharp rise; one, the US Food and Drug Administration’s approval for the generic version of an ulcerative colitis drug Lialda.....

TO READ THE FULL STORY, SUBSCRIBE NOW

Already a premium subscriber? LOGIN NOW.

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.

 

Advertisement
Ad
Ad
  
X

Share Box

Permalink